EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q2 2021 Results - Earnings Call Transcript

LYON, France, August 25, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the second quarter of 2021 and provided an update on strategic and operational developments.

EDAP Reports Second Quarter 2021 Results and Provides Operational Update

LYON, France, August 4, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, reports today select preliminary unaudited second quarter financial and operating results. The company anticipates reporting total second quarter revenue of approximately EUR 10.4 million (USD $12.4 million), representing an increase of 11.8% over EUR 9.3 million (USD $10.3 million) in the second quarter of 2020. First half total company revenue of EUR 20.7 million (USD $24.8 million) increased 22.5% over EUR 16.9 million (USD $18.7 million) for the first half of 2020.

EDAP Announces Select Preliminary Unaudited Second Quarter 2021 Results

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q1 2021 Results - Earnings Call Transcript

Shares of Edap TMS (NASDAQ:EDAP) rose after the company reported Q1 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.03, which beat the estimate of ($0.01).

Recap: Edap TMS Q1 Earnings

LYON, France, May 11, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter of 2021 and provided an update on strategic and operational developments.

EDAP Reports First Quarter 2021 Results and Provides Operational Update

Company to host conference call and webcast on Wednesday , May 12 at 8:30 am EDT

EDAP TMS SA to Announce First Quarter 2021 Financial Results on May 11, 2021

The stock price of EDAP TMS S.A. (NASDAQ: EDAP) decreased by over 14% pre-market.

EDAP Stock: Over 14% Decrease Pre-Market Explanation

LYON, France, April 23, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced that the price of its offering of American Depositary Shares (“ADS”) has been set at $6.75 per ADS and that the number of offered ADSs is 4,150,000 for an amount of approximately $28 million. The closing of the offering is expected to occur on April 27, 2021, subject to customary closing conditions.

EDAP Announces Pricing of Follow-On Offering

LYON, France, April 22, 2021 -- EDAP TMS S.A. (NASDAQ: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today the launch of a follow-on public offering of its American Depositary Shares, or ADSs, each representing one ordinary share of the Company.

EDAP Announces Launch of Follow-On Offering

The company is already growing sequentially, even if 2020 revenues were down on those in 2019. Still small in relation to a large and growing TAM, and working on an attractive business model, this is an attractive growth story.

EDAP TMS: A Little Medical Growth Gem

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q4 2020 Results - Earnings Call Transcript

Shares of Edap TMS (NASDAQ:EDAP) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 175.00% over the past year to $0.03, which missed the estimate of $0.08.

Recap: Edap TMS Q4 Earnings

LYON, France, March 30, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter of 2020 and provided an update on strategic and operational developments.

EDAP Reports Fourth Quarter 2020 Results and Provides Operational Update

EDAP TMS S.A. (EDAP) was a big mover last session on higher-than-average trading volume.

EDAP TMS S.A. (EDAP) Stock Jumps 18.8%: Will It Continue to Soar?

Edap TMS (NASDAQ:EDAP) releases its next round of earnings this Tuesday, March 30. Here is Benzinga's essential guide to Edap TMS's Q4 earnings report.

A Preview Of Edap TMS's Earnings

EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, announces today that the company has selected Medical Technology Partners (MTP) and Argenta Advisors, two leading reimbursement consultancies, to further expand coverage, accelerate market access and secure future payment rates for the company's Focal One high intensity focused ultrasound (HIFU) procedure in the US. The announcement follows the establishment of a Category 1 CPT code, and physician reimbursement for HIFU, that went into effect on January 1, 2021.

EDAP Selects Leading Reimbursement Consultancies MTP and Argenta Advisors to Expand Market Access and Coverage of HIFU in the US

LYON, France, January 19, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that Marc Oczachowski, President and CEO, will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 10:00 a.m. ET.

EDAP to Participate in B. Riley Securities Virtual Oncology Investor Conference

LYON, France, January 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, announced today positive 24 month interim results from the “HIFI” study comparing outcomes from high intensity focused ultrasound (HIFU) versus radical prostatectomy (RP) in a population of prostate cancer patients. This study is sponsored by the French Association of Urology (AFU) and supported by the French Ministry of Health. The results were presented at the AFU Congress in November 2020.

EDAP Announces Positive 24 Month Interim Results of French Urology Association (AFU) Sponsored Clinical Study comparing HIFU to Radical Prostate Surgery

EDAP TMS (EDAP) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

EDAP TMS (EDAP) Surges: Stock Moves 6% Higher

LYON, France, January 5, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy based therapies, today announced that it will participate in the 10th Annual LifeSci Partners Corporate Access Event, January 6-8 and 11-14, 2021.

EDAP to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event

LYON, France, December 30, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy- based therapies, announced today two new Focal One sales to leading U.S. healthcare institutions. The company announced a bundled sale of Focal One and Exact Vu to the University of California, San Francisco Medical Center (UCSF) and a Focal One sale to Cleveland Clinic. Both sales were completed during the fourth quarter.  

EDAP Announces End of the Year Focal One® Sales

Final rules establish, for the first time, a Category 1 CPT code and reimbursement to physicians performing ablation of malignant prostate tissue with HIFU in the US

EDAP Announces Final U.S. 2021 Reimbursement Rules for High Intensity Focused Ultrasound (HIFU)

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don't make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are now in a stock pickers market where fundamentals of a stock have more effect on the price than the overall direction of the market. As a result we observe sudden and large changes in hedge fund positions depending on the news flow. Let's take a look at the hedge fund sentiment towards EDAP TMS S.A. (NASDAQ:EDAP) to find out whether there were any major changes in hedge funds' views.

Is EDAP TMS S.A. (EDAP) A Good Stock To Buy?

EDAP TMS S.A. (EDAP) CEO Marc Oczachowski on Q3 2020 Results - Earnings Call Transcript

News for EDAP TMS Stock (EDAP)